Teva Secures Key FDA Win for Biosimilar Pipeline

Edgen Stock

·Mar 30 2026, 12:24

Share to

Share to

Copy link

Key Takeaways

Teva Pharmaceutical announced major advancements for its biosimilar portfolio, securing a key U.S. approval and advancing another candidate in both the U.S. and Europe. These regulatory wins bolster the company's "Pivot to Growth" strategy, aimed at competing in lucrative biologic drug markets.

The U.S. FDA approved PONLIMSI on March 30, 2026, Teva's biosimilar version of the osteoporosis drug Prolia.
Regulatory applications for a biosimilar to the allergy and asthma drug Xolair were accepted by both the U.S. FDA and the EMA.
These milestones validate Teva's strategy to compete in multi-billion dollar drug markets and build new revenue streams.

FDA Approves Osteoporosis Drug PONLIMSI on March 30

Teva Pharmaceutical Industries secured a significant regulatory victory on March 30, 2026, with the U.S. Food and Drug Administration (FDA) approving PONLIMSI™ (denosumab-adet). The drug is a biosimilar to Amgen's blockbuster osteoporosis treatment, Prolia®, and is approved for all its indications. This approval marks a critical step in Teva's "Pivot to Growth" strategy, which focuses on developing high-value biosimilars to drive future revenue. The U.S. green light follows a prior marketing authorization from the European Medicines Agency (EMA) in November 2025, establishing a strong regulatory foundation for the drug's global commercial launch.

Dual Filings for Xolair Biosimilar Signal Global Push

In a parallel development strengthening its pipeline, Teva announced that both the U.S. FDA and the EMA have accepted its regulatory filings for a proposed biosimilar to Xolair® (omalizumab). This coordinated submission targets the lucrative markets for allergic asthma, chronic sinusitis, and other IgE-mediated conditions currently dominated by the Novartis drug. The simultaneous acceptance by two of the world's most stringent regulatory bodies suggests a comprehensive and robust data package. This positions Teva to efficiently challenge a blockbuster biologic on two continents, underscoring the company's operational and regulatory capabilities in its push into complex generics.